RBC Sees Strong Opzelura Sales Offset by Regulatory Uncertainty
RBC said Incyte's Q3 performance was supported by strong Opzelura sales, while regulatory uncertainty remained a concern.
RBC said Incyte's Q3 performance was supported by strong Opzelura sales, while regulatory uncertainty remained a concern.